An interventional study of PRP injection and Alprostadil 20 micrograms in Erectile Dysfunction Due to General Medical Condition, Erectile Dysfunction Following Radical Prostatectomy and Erectile Dysfunction Associated With Type 2 Diabetes Mellitus, sponsored by Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari. Enrolling by invitation at 1 site in Italy. Open to male participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2025-10-02.
Sponsored by Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing platelet rich plasma in Erectile Dysfunction — 2 open to participants now, 3 under way, none of them phase 3. platelet rich plasma · Erectile Dysfunction.
Among the 12 studies testing platelet rich plasma in Erectile Dysfunction, this one is the 4th largest by planned enrollment, is one of 2 that started in 2023, is one of 3 with no phase, and was the 11th registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →2 of the 12 studies testing platelet rich plasma in Erectile Dysfunction are open now, in 2 countries. Recruiting first, the newest first:
University of Manitoba · Sites in Canada
Ages 30–70 · Men only · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 30 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 2
First in 2019; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 60 is below the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 60 across the 12 interventional studies. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 10 most frequent:
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari is the lead sponsor of 47 studies on the registry; 11 are open to participants now.
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari has 1 study filed under Erectile Dysfunction — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing platelet rich plasma in Erectile Dysfunction, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Patients are randomized into 2 groups (A and B), subsequently group A is subjected to a cycle of 6 weekly injections of 3 ml of autologous PRP while group B is subjected to 6 weekly injections of 1 ml of caverject (alprostadil) 20 mcg. After 4 (four) weeks the groups will be crossed, so group A will be subjected to 6 weekly injections of 1 ml of caverject (alprostadil) 20 mcg while group B will be subjected to a cycle of 6 weekly injections of 3 ml of autologous PRP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 ML OF PRP
Drug: PRP injection
CAVERJECT 1 ML
Drug: Alprostadil 20 micrograms
3 ML OF PRP
1 ML
Change in erectile function
Change in erectile function defined as the % of patients in each group achieving MCID in the IIEF-EF domain from baseline to 24 weeks (i.e. 12 weeks after the end of full treatment): * MCID (Minimal clinically important differences) is based on the severity of ED at baseline as: * Improvement of 5 or points more in IIEF score for patients with moderate ED (8-11) at baseline * Improvement of 2 or more points in IIEF score for patients with severe ED (5-7) at baseline
Time frame: 24 WEEKS
EHS
Time frame: change from baseline and at 8 weeks, 16 weeks, and 24 weeks Any value above 0 (0 = The penis does not enlarge)
Time frame: 24 WEEKS
The percentage of patients in each group who achieve MCID in the IIEF-EF domain from baseline after treatment with PRP
MCID (Minimal Clinically Important Differences) is defined on the severity of ED at baseline as: * An improvement of 5 or more points in the IIEF score for patients with moderate ED (8-11) at baseline * An improvement of 2 or more points in the IIEF score for patients with severe ED (5-7) at baseline
Time frame: 24 WEEKS
The percentage of patients in each group who achieve MCID in the IIEF-EF domain from baseline after treatment with prostaglandin
MCID (Minimal Clinically Important Differences) is defined on the severity of ED at baseline as: * An improvement of 5 or more points in the IIEF score for patients with moderate ED (8-11) at baseline * An improvement of 2 or more points
Time frame: 24 WEEKS
The difference in the IIEF score from baseline to the end of treatment between the PRP group and the prostaglandin-treated group.
The difference in the IIEF score from baseline to the end of treatment between the PRP group and the prostaglandin-treated group.
Time frame: 24 WEEKS
SEP
Change in SEP: * Response to questions 2 and 3 (SEP-Q2: Were you able to insert your penis into your partner's vagina? / SEP-Q3: Did your erection last long enough to allow you to have successful intercourse?) * Change from baseline (= "YES" response) o At T1 (2 weeks after the end of the first cycle), T2 (2 weeks after the end of the second cycle), and T3 (3 months after the end of the complete treatment)
Time frame: 24 WEEKS
GAQ
Response to GAQ questions 1 and 2 (GAQ-Q1: Has the treatment you are taking improved your erectile function? / GAQ-Q2: If yes, has the treatment improved your ability to engage in sexual activity?) Change at T1 (2 weeks after the end of the first cycle), T2 (2 weeks after the end of the second cycle), and T3 (3 months after the end of the complete treatment) o Change from baseline (= "YES" response)
Time frame: 24 WEEKS
QEQ
At T1 (2 weeks after the end of the first cycle), T2 (2 weeks after the end of the second cycle), and T3 (3 months after the end of the complete treatment) o Improvement of 2 or more in the score
Time frame: 24 WEEKS
Change in EDITS between PRP vs. prostaglandins
At T1 (2 weeks after the end of the first cycle) and T2 (2 weeks after the end of the second cycle)
Time frame: At T1 (2 weeks after the end of the first cycle) and T2 (2 weeks after the end of the second cycle)
Change in TSS between PRP vs. prostaglandins
Change in TSS between PRP vs. prostaglandins at T3 (3 months after the end of the complete treatment)
Time frame: 3 months after the end of the complete treatment
Change in SHIM
Change in SHIM * At T1 (2 weeks after the end of the first cycle), T2 (2 weeks after the end of the second cycle), and T3 (3 months after the end of the complete treatment) * Improvement of 2 or more points in the score
Time frame: 24 WEEKS
ECDPD - Peak Systolic Velocity (PSV)
ECDPD - Peak Systolic Velocity (PSV): * To assess penile hemodynamics from baseline to T1 (2 weeks after the end of the first cycle), T2 (2 weeks after the end of the second cycle), and T3 (3 months after the end of the complete treatment) * Recording of arterial penile velocity (cm/s) o Improvement in cm/s (any \> 30 cm/s)
Time frame: 24 WEEKS
ECDPD - Resistance Index (RI)
ECDPD - Resistance Index (RI): * To assess penile hemodynamics from baseline to T1 (2 weeks after the end of the first cycle), T2 (2 weeks after the end of the second cycle), and T3 (3 months after the end of the complete treatment) * Penile vascular resistance index (ratio) o Improvement (any increase up to the normal value - 0.9)
Time frame: 24 WEEKS
ECDPD - End-Diastolic Velocity (EDV)
ECDPD - End-Diastolic Velocity (EDV): * To assess penile hemodynamics from baseline to T1 (2 weeks after the end of the first cycle), T2 (2 weeks after the end of the second cycle), and T3 (3 months after the end of the complete treatment) * Recording of residual flow in a vessel at the end of the diastolic phase (cm/s) * Improvement in cm/s (any decrease in cm/s)
Time frame: 24 WEEKS
Adverse events
Adverse events: Number of participants who experienced treatment-related adverse events. Defined as: skin reaction (e.g., swelling, erythema, and warmth), discomfort at the injection site, penile pain, change in penile appearance, new sexual problems, and any systemic reaction observed by investigators or concerns expressed by patients o At T1 (2 weeks after the end of the first cycle), T2 (2 weeks after the end of the second cycle), and T3 (3 months after the end of the complete treatment)
Time frame: 24 WEEKS
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Apr 2023 to primary completion in Nov 2024, 19 months.
Of 115 non-industry interventional studies with no phase under Erectile Dysfunction, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's 19 months is below that.
Counting every sponsor, half of 137 studies reached it within 32 months; a quarter within 14 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Platelet rich plasma
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari